AI 热点

Isomorphic Labs 完成 50 亿美元融资,半年内第二轮

The Decoder更新于 11月17日 23:37

Isomorphic Labs raises $5 billion in its second mega-round within six months

AI 导读

Alphabet 旗下 AI 药物发现公司 Isomorphic Labs 完成 50 亿美元融资,由 Greenoaks 和 Sequoia Capital 联合领投,Andreessen Horowitz 新加入,Alphabet 及全部现有投资方跟投。这是该公司六个月内第二轮大额融资,此前在 2026 年 5 月已融资 21 亿美元。资金将用于推进其自研平台 IsoDDE(Isomorphic Drug Design Engine)和推动药物管线进入临床试验;公司称 IsoDDE 在 AlphaFold 3 基础上进一步预测药物结合与对接位点。Isomorphic Labs 成立于 2021 年,与 Novartis、Eli Lilly、Johnson & Johnson 有合作,目前尚无获批药物。

推荐理由

AI 评分 72

Isomorphic Labs 半年内再融 50 亿美元,资金将用于推进 IsoDDE 平台和药物管线进入临床试验。

主题

标签

正文

Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months. Greenoaks and Sequoia Capital co-led the round, joined by new backer Andreessen Horowitz along with Alphabet and all existing investors.

The company had already raised $2.1 billion back in May 2026. The money will go toward advancing its in-house platform IsoDDE (Isomorphic Drug Design Engine) and pushing its drug pipeline toward clinical trials. IsoDDE goes beyond AlphaFold 3, according to the company founded in 2021, and aims to better predict drug binding and docking sites. Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug to show for it yet.

The company is led by Demis Hassabis, who stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet's Chief Scientist. Hassabis won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold.

Deepmind's original AlphaFold team was disbanded in July 2026 . Many researchers moved to Isomorphic Labs or were reassigned to other projects. Nearly a quarter left Deepmind entirely. Deepmind still shipped AlphaGenome 2 in early November 2026, which predicts how DNA variants affect gene activity in specific cell types.

来源

The Decoder